中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 8
Aug.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(8): 1845-1856

Risk factors for rebleeding after endoscopic therapy for esophageal and gastric varices in liver cirrhosis patients and construction of a nomogram model

DOI: 10.12449/JCH260817
  • 1.

    Department of Gastroenterology，The Second People’s Hospital of Lanzhou，Lanzhou 730000，China

  • 2.

    Day Ward，Department of Traditional Chinese Medicine，The Second People’s Hospital of Lanzhou，Lanzhou 730000，China

  • 3.

    Department of Pathology，The Second People’s Hospital of Lanzhou，Lanzhou 730000，China

  • 4.

    Department of Gastroenterology，The 940th Hospital of Joint Logistics Support Force of PLA，Lanzhou 730050，China

Research funding:

Gansu Provincial Health and Wellness Industry Scientific Research Project (GSWSKY2023-34);

Lanzhou Youth Scinence and Technology Talent Innovation Project (2024-QN-39)

More Information
  • Corresponding author: Du Hongwei， dhwdyx@163.com （ORCID： 0000-0001-7032-6792）
  • Received Date: 2026-01-11
  • Accepted Date: 2026-04-27
  • Published Date: 2026-08-25
    Abstract
  •   Objective  To investigate the risk factors for rebleeding after endoscopic therapy for esophageal and gastric varices in liver cirrhosis patients， to construct a clinical predictive model， and to provide a reference for predicting rebleeding in the early stage， reducing the incidence rate of rebleeding， and improving the clinical outcome of patients.  Methods  A retrospective analysis was performed for the clinical data of 194 liver cirrhosis patients with gastroesophageal variceal bleeding who received initial endoscopic therapy at Department of Gastroenterology， The Second People’s Hospital of Lanzhou， from January 1， 2021 to May 31， 2025. According to whether rebleeding occurred within 1 year after endoscopic therapy， the patients were divided into rebleeding group and non-rebleeding group. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups. The patients enrolled were randomly divided into a training set and a validation set at a ratio of 7∶3. In the training set， the Lasso regression analysis was used to obtain optimal predictive variables， and the factors that might affect prognosis were included in the univariate and multivariate Logistic regression analyses to identify independent predictive factors for rebleeding after endoscopic therapy for esophageal and gastric varices in liver cirrhosis patients， which were used to construct a nomogram model. In both the training set and the validation set， the receiver operating characteristic （ROC） curve and the calibration curve were used to assess the discriminatory ability and calibration of the model， and decision curve analysis and the clinical impact curve were used to assess the clinical practicability of the model.  Results  Among the 194 liver cirrhosis patients with esophageal and gastric varices， 116 （59.79%） experienced rebleeding within 1 year after endoscopic therapy， with 76 patients in the training set and 40 patients in the validation set. In the training set， the Lasso regression analysis and the univariate and multivariate Logistic regression analyses showed that etiology of liver cirrhosis （odds ratio ［OR］=3.540， 95% confidence interval ［CI］： 1.520 — 7.150， P<0.001）， Child-Pugh class （OR=3.560， 95%CI： 1.380 — 9.500， P=0.019）， severity of esophageal and gastric varices （OR=8.190， 95%CI： 3.568 — 17.850， P=0.026）， and main portal vein diameter （OR=2.954， 95%CI： 1.349 — 15.030， P=0.044） were independent predictive factors for rebleeding of esophageal and gastric varices in liver cirrhosis patients. A nomogram model was constructed based on the above independent predictive factors. The ROC curve analysis showed that this model had an area under the ROC curve of 0.845 （95%CI： 0.778 — 0.912） in the training set and 0.801 （95%CI： 0.798 — 0.868） in the validation set. The model had an index of concordance of 0.832 in the training set and 0.820 in the validation set， suggesting that the model had a good discriminatory ability. The Hosmer-Lemeshow test showed P values of 0.320 and 0.550 in the training set and validation set， respectively， the calibration curve indicated that the predicted probabilities of the nomogram model were in good concordance with the actual observed probabilities， suggesting that the model had good calibration. The decision curve analysis and the clinical impact curve showed that the model had good clinical utility.  Conclusion  The nomogram model based on etiology of liver cirrhosis， Child-Pugh class， severity of esophageal and gastric varices， and main portal vein diameter has a certain clinical value in predicting the risk of rebleeding from esophageal and gastric varices in liver cirrhosis.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    Garcia-Tsao G, Abraldes J G, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2017, 65( 1): 310- 335. DOI: 10.1002/hep.28906.
    [2]
    Jakab S S, Garcia-Tsao G. Evaluation and management of esophageal and gastric varices in patients with cirrhosis[J]. Clin Liver Dis, 2020, 24( 3): 335- 350. DOI: 10.1016/j.cld.2020.04.011.
    [3]
    de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [4]
    Zhan J Y, Chen J, Yu J Z, et al. Prognostic model for esophagogastric variceal rebleeding after endoscopic treatment in liver cirrhosis: A Chinese multicenter study[J]. World J Gastroenterol, 2025, 31( 2): 100234. DOI: 10.3748/wjg.v31.i2.100234.
    [5]
    Li J, Li J, Ji Q, et al. Nomogram based on spleen volume expansion rate predicts esophagogastric varices bleeding risk in patients with hepatitis B liver cirrhosis[J]. Front Surg, 2022, 9: 1019952. DOI: 10.3389/fsurg.2022.1019952.
    [6]
    Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on the diagnosis and treatment of esophageal and gastric variceal rupture bleeding in cirrhotic portal hypertension(2025 edition)[J]. Chin J Dig Surg, 2025, 24( 3): 271- 280. DOI: 10.3760/cma.j.cn115610-20241228-00590.

    中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2025版)[J]. 中华消化外科杂志, 2025, 24( 3): 271- 280. DOI: 10.3760/cma.j.cn115610-20241228-00590.
    [7]
    Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 39( 3): 527- 538.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39( 3): 527- 538.
    [8]
    Zhang W H, Wang Y L, Chu J D, et al. Investigation report on endoscopic management of esophagogastric variceal bleeding by Chinese endoscopists[J]. Medicine, 2022, 101( 42): e31263. DOI: 10.1097/MD.0000000000031263.
    [9]
    Li Xinhui, Qi Xingshun, Wang Jing, et al. Construction and optimization of a quality control system for endoscopic management of esophageal and gastric varices in cirrhosis[J]. Clin J Med Off, 2026, 54( 1): 1- 5, 10. DOI: 10.16680/j.1671-3826.2026.01.01.

    李鑫会, 祁兴顺, 王静, 等. 肝硬化食管胃静脉曲张内镜管理质量控制体系构建与优化[J]. 临床军医杂志, 2026, 54( 1): 1- 5, 10. DOI: 10.16680/j.1671-3826.2026.01.01.
    [10]
    Yang J, Ge K, Chen L, et al. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: A meta-analysis[J]. Eur J Gastroenterol Hepatol, 2019, 31( 12): 1518- 1526. DOI: 10.1097/MEG.0000000000001442.
    [11]
    Duan X W, He X, Yan H Z, et al. Analysis of complications and risk factors other than bleeding before and after endoscopic treatment of esophagogastric variceal bleeding in patients with liver cirrhosis[J]. Can J Gastroenterol Hepatol, 2023, 2023: 7556408. DOI: 10.1155/2023/7556408.
    [12]
    Wu L, Fang Q Q, Huang X Q, et al. Risk factors associated with failure of endoscopic combined treatment to prevent varices rebleeding in patients with liver cirrhosis[J]. Expert Rev Gastroenterol Hepatol, 2023, 17( 3): 301- 308. DOI: 10.1080/17474124.2023.2181787.
    [13]
    Tao K, Shan X, He B B, et al. Sequential endoscopic treatment for esophageal and gastric variceal bleeding significantly reduces patient mortality and rebleeding rates[J]. Ther Adv Gastroenterol, 2024, 17: 17562848241299743. DOI: 10.1177/17562848241299743.
    [14]
    Ding S Y, Lu S Y, Cui L Y, et al. Association between duration of alcohol consumption and risk of hematemesis in patients with alcoholic cirrhosis complicated by esophagogastric variceal bleeding: A case-control study[J]. BMC Gastroenterol, 2025, 25( 1): 849. DOI: 10.1186/s12876-025-04444-3.
    [15]
    Taleb A, Ibrahim M. Gastrointestinal bleeding in liver cirrhosis[M]// Recent advances in liver cirrhosis related complications. Academic Press, 2025: 59- 69.
    [16]
    Lin C C, Huang Y S. Portal vein thrombosis and esophageal-gastric variceal bleeding in cirrhosis: Shared risk factors and causal relationship[J]. BMC Gastroenterol, 2025, 25( 1): 500. DOI: 10.1186/s12876-025-04094-5.
    [17]
    Yang Jianbo, Huang Xiaomei, He Yuanjing, et al. Outcomes of endoscopic treatment of esophagogastric variceal bleeding and construction and validation of a 1-year rebleeding risk prediction model[J]. J Sichuan Univ Med Sci, 2025, 56( 1): 284- 290. DOI: 10.12182/20250160106.

    杨建波, 黄小梅, 何远静, 等. 食管胃底静脉曲张破裂出血内镜治疗效果及1年内再出血风险预测模型的构建及验证[J]. 四川大学学报(医学版), 2025, 56( 1): 284- 290. DOI: 10.12182/20250160106.
    [18]
    Zhu Yingjing, Wu Jie, Tian Xinyue, et al. Endoscopic tissue glue injection and esophageal variceal ligation in treatment of patients with hepatitis B-induced liver cirrhosis and esophageal and gastric varices bleeding[J]. J Pract Hepatol, 2025, 28( 5): 731- 734. DOI: 10.3969/j.issn.1672-5069.2025.05.023.

    朱颖静, 吴洁, 田鑫越, 等. 内镜下组织胶注射治疗乙型肝炎肝硬化食管胃底静脉曲张破裂出血患者疗效分析[J]. 实用肝脏病杂志, 2025, 28( 5): 731- 734. DOI: 10.3969/j.issn.1672-5069.2025.05.023.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (13) PDF downloads(0) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return